Because thiotepa, a key agent in HDT/ASCT for PCNSL, has been unavailable since 2011 in Japan, the HDT regimens used were not uniform. There were no significant differences in OS and PFS between upfront and salvage HDT/ASCT. With a median duration of follow-up of 44 months, the 5-year overall survival (OS) and progession-free survival (PFS) were 54.9% and 38.4%, respectively. The median patient age was 54 years (range, 20 to 74 years), and 65 patients were treated in an upfront setting. We queried the Japan Society for Hematopoietic Cell Transplantation Registry for 2006 to 2015 to analyze the outcomes of 102 patients with primary CNS lymphoma (PCNSL) who underwent first HDT/ASCT. High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to improve the prognosis of patients with central nervous system (CNS) lymphoma. 15 Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.14 Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan.13 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.12 Department of Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.11 Department of Hematology, Tenri Hospital, Tenri, Japan.10 Third department of Internal Medicine, Yamagata University School of Medicine, Yamagata, Japan.9 Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.8 Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.7 Department of Hematology and Immunology, Kanazawa Medical University, Uchinada, Japan.6 Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.5 Department of Hematology, Kawasaki Medical School, Kurashiki, Japan.4 Medical Oncology Service, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.3 Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.Electronic address: 2 Division of Hematology and Stem Cell Transplantation, Shizuoka Cancer Center, Nagaizumi-cho, Japan. 1 Department of Hematology, Kawasaki Medical School, Kurashiki, Japan.Jackson: BMS: Consultancy, Honoraria, Speakers Bureau Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau J and |J: Consultancy, Honoraria, Speakers Bureau Pfizer: Consultancy, Honoraria GSK: Consultancy, Honoraria, Speakers Bureau Sanofi: Consultancy, Honoraria, Speakers Bureau Oncopeptides: Consultancy. Cairns: Takeda: Research Funding Amgen: Research Funding Celgene/BMS: Honoraria. Owen: Astra-Zeneca: Honoraria Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees Beigene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Drayson: Abingdon Health: Current equity holder in private company. ![]() Kaiser: GSK: Consultancy Karyopharm: Consultancy Takeda: Honoraria Seattle Genetics: Consultancy Pfizer: Consultancy Janssen: Honoraria, Research Funding BMS/Celgene: Honoraria, Research Funding AbbVie: Consultancy. Jenner: Takeda: Consultancy GSK: Consultancy Pfizer: Consultancy Janssen: Consultancy, Honoraria BMS/Celgene: Consultancy, Honoraria. Cook: Sanofi: Consultancy Karyopharm: Consultancy Amgen: Consultancy BMS/Celgene: Consultancy, Research Funding Janssen: Consultancy, Research Funding Takeda: Consultancy, Research Funding. Henderson: Celgene/BMS: Research Funding Amgen: Research Funding Takeda: Honoraria. Davies: Takeda: Consultancy, Honoraria Abbvie: Consultancy, Honoraria Amgen: Consultancy, Honoraria Celgene/BMS: Consultancy, Honoraria Roche: Consultancy, Honoraria Janssen: Consultancy, Honoraria. Menzies: Takeda: Research Funding Celgene/BMS: Research Funding Amgen: Research Funding. Pawlyn: Janssen: Consultancy, Honoraria, Other: Travel support Celgene/BMS: Consultancy, Honoraria Sanofi: Consultancy, Honoraria Abbvie: Consultancy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |